{"preliminary_commentary":{"by_channel":{"x_thread":3},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build."},"free_build":{"available":false},"name":"STOPTRAFFIC-1","nct_id":"NCT04599140","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=stoptraffic-1-nct04599140. The price is an estimate of verified statements from the commentary indexed so far, fixed at order. Final coverage is set when the report is built. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_usd":750,"size":"focused","size_rule":"Focused: 1–150 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"MONOTHERAPY STAGE: Patients receive SX-682 orally PO BID on days 1-21 in the absence of disease progression or unacceptable toxicity.\n\nCOMBINATION STAGE: Patients receive SX-682 PO BID on days 1-56 and nivolumab IV over 30 minutes on days 1 and 29. Treatment repeat every 56 days weeks for up to 12 cycles in the absence of disease progression or unacceptable toxicity.","label":"Treatment (SX-682, nivolumab)","type":"EXPERIMENTAL"}],"collaborators":["Bristol-Myers Squibb","Syntrix Biosystems, Inc."],"completion_date":{"date":"2026-07-31","type":"ESTIMATED"},"conditions":["Metastatic Colon Adenocarcinoma","Metastatic Colorectal Carcinoma","Metastatic Rectal Adenocarcinoma","Stage III Colon Cancer AJCC v8","Stage III Rectal Cancer AJCC v8","Stage IIIA Colon Cancer AJCC v8","Stage IIIA Rectal Cancer AJCC v8","Stage IIIB Colon Cancer AJCC v8","Stage IIIB Rectal Cancer AJCC v8","Stage IIIC Colon Cancer AJCC v8","Stage IIIC Rectal Cancer AJCC v8","Stage IV Colon Cancer AJCC v8","Stage IV Rectal Cancer AJCC v8","Stage IVA Colon Cancer AJCC v8","Stage IVA Rectal Cancer AJCC v8","Stage IVB Colon Cancer AJCC v8","Stage IVB Rectal Cancer AJCC v8","Stage IVC Colon Cancer AJCC v8","Stage IVC Rectal Cancer AJCC v8","Unresectable Colon Adenocarcinoma","Unresectable Rectal Adenocarcinoma"],"enrollment":{"count":51,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CXCR1/2 Inhibitor SX-682","otherNames":["SX 682","SX-682","SX682"],"type":"DRUG"},{"name":"Nivolumab","otherNames":["BMS-936558","MDX-1106","NIVO","ONO-4538","Opdivo"],"type":"BIOLOGICAL"}],"last_update":"2026-07-20","lead_sponsor":"M.D. Anderson Cancer Center","official_title":"Phase Ib/II Trial of SX-682 in Combination With Nivolumab for Refractory RAS Mutated (RAS) Microsatellite Stable (MSS) Metastatic Colorectal Cancer (mCRC) (STOPTRAFFIC-1)","overall_status":"ACTIVE_NOT_RECRUITING","phases":["PHASE1","PHASE2"],"primary_completion_date":{"date":"2026-07-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Incidence of adverse events (AEs)","timeFrame":"Up to 2 years"}],"references":[],"start_date":{"date":"2020-10-14","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"SX-682 and Nivolumab for the Treatment of RAS-Mutated, MSS Unresectable or Metastatic Colorectal Cancer, the STOPTRAFFIC-1 Trial","url":"https://clinicaltrials.gov/study/NCT04599140"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.0","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/stoptraffic-1-nct04599140"}